From Drinks To Drugs: DyDo Charts Course For Pharma Entry
A company with its main business in soft drinks and canned coffee might seem an unlikely entrant into the prescription pharma business, but Japan’s DyDo Group maintains it has solid reasons and a robust business plan for what it sees as an important future growth driver.
You may also be interested in...
Asajes Ventures sees itself as offering a unique new mixed business model of venture capital and local development activity for smaller Western companies looking to develop their product or pipeline assets in Japan and China, aided by new opportunities from a rapidly reforming regulatory environment.
Join us for an audio roundup of major events in the global biopharma industry over the past week, as reported by Scrip.
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.